Nephrotic Syndrome Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Nephrotic syndrome is a clinical syndrome defined by the tetrad of: (1) heavy proteinuria (>3.5g per 24 hours in adults, >40mg/m²/hour in children), (2) hypoalbuminaemia (serum albumin <30 g/L), (3) generalised oedema (peripheral, periorbital, ascites, and in severe cases pleural effusion), and (4) hyperlipidaemia with lipiduria. It results from increased glomerular permeability to proteins, with loss of oncotic pressure causing fluid extravasation.

Management has two parallel tracks:

• Disease-specific immunosuppressive treatment targeting the underlying glomerular pathology (when primary/immune-mediated)
• Symptomatic management addressing the consequences of nephrosis — oedema, thromboembolism risk, infection susceptibility, dyslipidaemia, and progressive kidney function loss

The cause of nephrotic syndrome determines the treatment approach entirely. Renal biopsy is mandatory in adults (except when diabetic nephropathy is the near-certain cause) to establish the histological diagnosis before initiating immunosuppression. In children with first presentation of nephrotic syndrome, empirical steroid treatment is standard without biopsy, as minimal change disease accounts for >80% of cases.

Complications of untreated or under-treated nephrotic syndrome include: (1) thromboembolic events (renal vein thrombosis, pulmonary embolism — driven by urinary loss of antithrombin III and protein C/S), (2) serious infections (pneumococcal peritonitis, cellulitis — due to loss of immunoglobulins and complement factors), (3) acute kidney injury from intravascular volume depletion, and (4) progression to chronic kidney disease.

Nephrotic syndrome is classified as primary (idiopathic) — arising from intrinsic glomerular disease — or secondary — arising as a manifestation of a systemic disease:

Primary (Idiopathic) Causes:

• Minimal Change Disease (MCD): Most common cause in children (80%+); also accounts for 10-15% of adult nephrotic syndrome. Light microscopy is normal; electron microscopy shows diffuse podocyte foot process effacement. Responds dramatically to corticosteroids (80-90% remission). Frequently relapsing course in 50-70% of children and 30-40% of adults.
• Focal Segmental Glomerulosclerosis (FSGS): Segmental sclerotic lesions affecting some (focal) glomeruli. Most common cause of primary nephrotic syndrome in adults, particularly Black patients. Variants (Columbia classification): tip, cellular, collapsing (worst prognosis), perihilar, NOS. Steroid resistance is common (50-70% primary FSGS). The PODOCIN (NPHS2) and WT1 gene mutations cause genetic FSGS.
• Membranous Nephropathy (MN): Most common primary cause of nephrotic syndrome in White adults over 40. Subepithelial immune complex deposits. 70-80% are PLA2R antibody-positive (M-type phospholipase A2 receptor antibody) — a disease-specific biomarker that guides treatment decisions and remission monitoring. Natural history: one-third spontaneous remission, one-third persistent nephrosis, one-third progressive CKD. THSD7A antibody positive in 2-3% (associated with cancer).
• Membranoproliferative Glomerulonephritis (MPGN): Complement dysregulation or immune complex-mediated; associated with C3 glomerulopathy; rare cause of nephrotic syndrome; overlaps with mixed cryoglobulinaemia (HCV).
• IgA Nephropathy with nephrotic features: Rare presentation; usually nephritic rather than nephrotic.

Secondary Causes (systemic diseases):

• Diabetic nephropathy: Leading secondary cause worldwide; characterised by mesangial expansion, GBM thickening, and Kimmelstiel-Wilson nodules; treatment centres on ACE-I/ARB and SGLT2 inhibitors (empagliflozin, dapagliflozin) rather than immunosuppression.
• Lupus nephritis (Class V — membranous lupus): May produce pure nephrotic syndrome; managed with hydroxychloroquine, mycophenolate mofetil (MMF), and calcineurin inhibitors (tacrolimus or voclosporin — FDA 2021).
• Amyloidosis (AL or AA): Heavy proteinuria from amyloid fibril deposition in glomeruli; AL amyloid treated with haematological therapies (bortezomib-based regimens, daratumumab); AA amyloid — treat underlying inflammatory disease.
• Pre-eclampsia: Massive proteinuria in pregnancy — delivery is definitive treatment.
• Viral causes: HIV-associated nephropathy (HIVAN — collapsing FSGS pattern), Hepatitis B-associated MN, Hepatitis C-associated MPGN.
• Drug-induced: NSAIDs (MCD pattern), penicillamine, gold (MN pattern), mercury compounds.

Before initiating disease-specific treatment, a structured assessment determines eligibility and treatment pathway:

Essential investigations:

• Urinary protein-to-creatinine ratio (uPCR) or 24-hour urine protein quantification
• Serum albumin, lipid panel (total cholesterol, LDL, triglycerides), full blood count, renal function (eGFR, creatinine), electrolytes
• Complement (C3, C4), ANA, ANCA, anti-dsDNA, anti-GBM antibodies (to exclude secondary/vasculitic causes)
• PLA2R antibody (for suspected membranous nephropathy — high specificity)
• Hepatitis B, C serology; HIV test
• Serum protein electrophoresis and urinary Bence Jones protein (if amyloid or myeloma suspected, especially in elderly)
• Renal biopsy — mandatory in adults with new-onset nephrotic syndrome of uncertain aetiology

Who is suitable for immunosuppressive treatment:

• Confirmed primary glomerulonephritis (MCD, FSGS, membranous nephropathy) on biopsy in the absence of active infection or uncontrolled comorbidity
• Children with first-episode nephrotic syndrome — empirical prednisolone without biopsy is standard

Immunosuppression contraindications or cautions:

• Active serious infection (sepsis, TB) — treat infection first
• Poorly controlled diabetes mellitus — steroids will worsen glycaemic control significantly; plan with endocrinologist
• Active malignancy — THSD7A-positive MN especially must exclude cancer before immunosuppression
• Significant osteoporosis — bone protection (calcium, vitamin D, bisphosphonate) before corticosteroids

A. Disease-Specific Immunosuppressive Therapy

Minimal Change Disease (MCD):

• First-line: Prednisolone 1mg/kg/day (maximum 80mg/day) for 4-16 weeks. Remission (uPCR <20 mg/mmol or urine protein <0.3g/day) expected in 80-90% of adults within 8-16 weeks, and in children within 4 weeks.
• Frequently relapsing / steroid-dependent MCD: Cyclophosphamide 2-3mg/kg/day for 8 weeks (induces sustained remission in 50-60%); or tacrolimus 0.05-0.1mg/kg/day (calcineurin inhibitor — high remission rate but relapse on cessation); or rituximab 375mg/m² IV (anti-CD20 monoclonal antibody) — increasingly used as steroid-sparing agent; RCT evidence supports rituximab for steroid-dependent MCD (RITURNS trial).
• Steroid-resistant MCD: Re-biopsy to exclude FSGS; if confirmed MCD — tacrolimus or rituximab. Consider genetic testing for podocin mutations.

Focal Segmental Glomerulosclerosis (FSGS):

• First-line: Prednisolone 1mg/kg/day (max 80mg) for at least 16 weeks (longer steroid trial than MCD). Approximately 30-50% of primary FSGS achieves complete or partial remission with steroids.
• Steroid-resistant or dependent FSGS: Tacrolimus 0.05-0.1mg/kg/day targeting trough levels 5-10 ng/mL; cyclosporin A 3-5mg/kg/day; mycophenolate mofetil (MMF) 750mg-1,500mg twice daily.
• Sparsentan (Filspari, Travere Therapeutics): Dual endothelin-angiotensin receptor antagonist (DEARA); FDA approved February 2023 for IgA nephropathy (full approval) and FSGS (accelerated approval based on DUPLEX trial). Reduces proteinuria significantly more than irbesartan alone in FSGS; an important advance as first non-immunosuppressive disease-modifying agent approved for FSGS.
• Genetic FSGS (NPHS2/WT1 mutations): Immunosuppression is ineffective; management is renoprotective (ACE-I, blood pressure control); preparation for renal replacement therapy.

Membranous Nephropathy (MN):

• Low-risk MN (baseline eGFR >60, proteinuria <4g/day): Conservative management with ACE-I/ARB + monitoring for 6-12 months, as spontaneous remission occurs in 30%.
• Medium-risk MN (proteinuria 4-8g/day, declining eGFR): Rituximab 375mg/m² IV x2 doses (1g IV x2 alternatively — Falk protocol).
• High-risk MN (proteinuria >8g/day, eGFR <60 or declining rapidly): The MENTOR trial (2019) established rituximab as superior to cyclosporin A for achieving complete or partial remission at 24 months (60% vs 20% complete remission at 24 months). Rituximab has replaced the Ponticelli regimen (alternating chlorambucil/cyclophosphamide and steroids) as standard first-line for high-risk primary MN in many centres.
• PLA2R antibody monitoring: Serial anti-PLA2R antibody titres guide treatment response — antibody clearance (immunological remission) precedes proteinuria remission by 3-6 months. Rising PLA2R titre signals relapse before clinical deterioration.

B. Symptomatic Management (All Causes)

Oedema management:

• Furosemide (loop diuretic) 40-240mg/day as first-line; dose titration to achieve 0.5-1kg daily weight loss. Oral furosemide absorption is reduced in severe nephrosis (GI oedema impairs absorption) — IV furosemide may be required.
• Metolazone 2.5-5mg orally (thiazide-like diuretic acting at different nephron segment) added to furosemide in diuretic-resistant oedema — produces synergistic effect (sequential nephron blockade); monitor electrolytes closely (risk of profound hypokalaemia).
• Salt restriction <2g sodium/day and fluid restriction 1.5L/day in severe oedema.
• Albumin infusion (20% human albumin): Used for severe symptomatic hypoalbuminaemia (<20 g/L) with refractory oedema, particularly to enhance diuretic response (IV furosemide following albumin bolus increases diuresis) and in patients with intravascular volume depletion at risk of AKI. Not routinely given for asymptomatic hypoalbuminaemia.

Anticoagulation:

• Nephrotic syndrome creates a hypercoagulable state due to urinary loss of antithrombin III, protein C, and protein S, combined with elevated fibrinogen and platelet hyperactivity.
• Prophylactic anticoagulation (low-molecular-weight heparin or warfarin/DOAC) is recommended when serum albumin <20 g/L, particularly in membranous nephropathy (highest thrombotic risk — renal vein thrombosis in up to 40%). Target INR 2-3 with warfarin if used. DOACs are increasingly used (apixaban, rivaroxaban) but evidence base is limited in nephrotic syndrome.
• Established thrombus (DVT, PE, renal vein thrombosis): full therapeutic anticoagulation for minimum 6 months or until remission.

Proteinuria reduction and renoprotection:

• ACE inhibitors (ramipril, lisinopril) or ARBs (losartan, irbesartan): Reduce intraglomerular pressure and proteinuria by 30-40% independent of BP-lowering effect. Maximise to tolerated dose. First-line for all secondary nephrotic syndrome (diabetic nephropathy) and as adjunct in primary nephropathies.
• SGLT2 inhibitors (empagliflozin, dapagliflozin): Evidence-based reduction in proteinuria and CKD progression in diabetic and non-diabetic CKD (CREDENCE, DAPA-CKD trials); increasingly used in nephrotic syndrome to provide additive proteinuria reduction.

Dietary and lifestyle management:

• Dietary protein 0.8-1.0g/kg/day ideal body weight — adequate to replace urinary losses without accelerating glomerular hyperfiltration.
• Lipid-lowering: statins (atorvastatin, rosuvastatin) for hyperlipidaemia — reduces cardiovascular risk; limited impact on disease course.
• Infection prophylaxis: Pneumovax 23 vaccination, Prevnar 13 (PCV13) vaccination, annual influenza vaccine; penicillin prophylaxis (phenoxymethylpenicillin 250mg twice daily) in children with recurrent nephrotic syndrome and history of serious infection.
• Bone protection: calcium 1,200mg/day + vitamin D 800 IU/day + bisphosphonate (alendronate) for patients on long-term corticosteroids.

Treatment outcomes vary significantly by histological diagnosis and treatment responsiveness:

• Minimal Change Disease (MCD): 80-90% achieve complete remission with first corticosteroid course. Even with frequent relapses, long-term renal prognosis is excellent — >95% preserve normal kidney function at 10 years. Rituximab achieves sustained remission (>12 months off all therapy) in 50-60% of steroid-dependent patients (RITURNS trial).
• FSGS (steroid-sensitive): Complete remission with steroids correlates with excellent long-term renal survival (90%+ at 10 years). Steroid-resistant FSGS carries far worse prognosis — approximately 50% reach ESRD within 5-10 years without effective immunosuppression. Sparsentan (DUPLEX trial) achieved 40% reduction in proteinuria vs ARB alone at 36 weeks in steroid-resistant FSGS.
• Membranous nephropathy (MENTOR trial results): Rituximab produced complete remission in 26% and partial remission in 34% (total 60%) at 24 months vs 20% complete remission with cyclosporin A. Anti-PLA2R antibody clearance (immunological remission) occurred in 87% with rituximab vs 35% with cyclosporin A — predicting lower relapse rates.
• Secondary nephrotic syndrome: Outcomes depend on underlying disease control. ACE-I/ARB + SGLT2 inhibitors reduce proteinuria by 30-50% and slow CKD progression by 30-40% in diabetic nephropathy (CREDENCE, DAPA-CKD trials). Lupus nephritis Class V: 60-70% achieve partial or complete remission with voclosporin + MMF (AURORA-1 trial).
• Symptomatic management benefits: Furosemide + metolazone achieves diuresis in 80%+ of diuretic-resistant oedema. Anticoagulation reduces thromboembolic events in high-risk MN patients. Salt restriction alone can reduce oedema by 1-2kg/week.

Corticosteroids (prednisolone):

• Short-term: weight gain, fluid retention, hyperglycaemia, hypertension, mood disturbance (euphoria or depression), insomnia, acne, susceptibility to infections (especially Pneumocystis jirovecii pneumonia [PJP] with prolonged high-dose — consider co-trimoxazole prophylaxis).
• Long-term (>3 months): osteoporosis (vertebral fractures — bone protection mandatory), adrenal suppression, cataracts, avascular necrosis of femoral head, growth retardation in children (use of alternate-day steroids or steroid-sparing agents preferred).

Cyclophosphamide: Haemorrhagic cystitis (prevent with adequate hydration and MESNA), gonadal toxicity (infertility — important counselling for young patients; fertility preservation options if indicated), bone marrow suppression, increased infection risk, bladder cancer risk (alkylating agent — cumulative dose-dependent). Maximum lifetime dose monitoring required.

Calcineurin inhibitors (tacrolimus, cyclosporin A): Nephrotoxicity (calcineurin inhibitor nephropathy — particularly with long-term use; afferent arteriole vasoconstriction causes ischaemic injury), hypertension, hyperkalaemia, hyperuricaemia, new-onset diabetes after transplant (NODAT) — especially tacrolimus, drug interactions (CYP3A4 pathway — numerous interactions), neurotoxicity (tremor, headache), gingival hyperplasia and hirsutism (cyclosporin A). Requires therapeutic drug monitoring (trough levels).

Rituximab: Infusion reactions (managed with premedication — methylprednisolone, antihistamine, paracetamol), prolonged B-cell depletion (increased infection risk — screen for hepatitis B reactivation before use, Pneumocystis pneumonia prophylaxis), hypogammaglobulinaemia with repeated dosing, and rare progressive multifocal leukoencephalopathy (PML).

Sparsentan: Teratogenicity (REMS programme required — pregnancy testing and contraception mandatory as per ENDOTHELIN class effects), fluid retention, anaemia; liver function monitoring required.

Diuretics: Electrolyte disturbances (hypokalaemia — particularly dangerous with furosemide + metolazone combination; hyponatraemia; hypomagnesaemia), volume depletion and AKI (over-diuresis; hold diuretics if AKI develops), ototoxicity (high-dose IV furosemide), and gout (urate retention).

Anticoagulation: Bleeding risk (major bleeding 1-3%/year with warfarin); drug interactions; need for monitoring (INR for warfarin). In heavy proteinuria, drug binding to albumin is altered, affecting pharmacokinetics.

Close follow-up is essential to monitor treatment response, detect complications, and adjust therapy:

During active immunosuppression:

• Fortnightly (first 2 months): uPCR, serum albumin, renal function, electrolytes, blood pressure, blood glucose (especially on steroids), full blood count.
• Monthly thereafter: Same parameters plus lipid panel, drug levels (tacrolimus trough) if on calcineurin inhibitor.
• PLA2R antibody (membranous nephropathy): Repeat every 3 months; clearance of antibody titre precedes clinical remission and guides treatment intensity.

Definitions of response (used to guide ongoing therapy):

• Complete remission: Proteinuria <0.3g/day (uPCR <20 mg/mmol) AND serum albumin normalised (>35 g/L).
• Partial remission: >50% reduction in proteinuria AND proteinuria <3.5g/day with stabilised renal function.
• Relapse: Return of proteinuria >3.5g/day (adults) or uPCR >200 mg/mmol (children) after remission.

Long-term surveillance:

• Renal function (eGFR) every 3-6 months once remission is established; annual if stable.
• Blood pressure monitoring — target <130/80 mmHg (KDIGO guidelines for CKD with proteinuria).
• Bone density (DEXA scan) at baseline and every 12 months on long-term corticosteroids; bisphosphonate treatment if T-score <-2.5 or declining.
• Cardiovascular risk assessment annually — nephrotic syndrome confers substantial CV risk through dyslipidaemia, hypertension, and proteinuria-driven endothelial dysfunction.

Childhood nephrotic syndrome: Growth monitoring on long-term steroids; alternate-day steroid regimen to minimise HPA suppression and growth effects; school attendance planning around infection vulnerability.

Transition to renal replacement therapy planning: If eGFR <30 mL/min/1.73m² and declining, refer to nephrology for dialysis access planning (arteriovenous fistula creation) and transplant assessment.

Treatment costs vary substantially by the drug used, disease course, and healthcare system:

Corticosteroids: Prednisolone is inexpensive — £5-15/month (UK), $10-30/month (USA), ₹100-300/month (India). However, monitoring and complication management add significant cost.

Calcineurin inhibitors:

• Tacrolimus: £100-300/month (UK NHS), $300-800/month (USA, brand Prograf); generic tacrolimus reduces cost by 60-80%.
• Cyclosporin A (Neoral): £80-250/month (UK), $200-600/month (USA).

Rituximab:

• Brand (MabThera/Rituxan): £3,000-5,000 per infusion (UK), $8,000-15,000 per infusion (USA).
• Biosimilar rituximab (Truxima, Rixathon): 30-50% cheaper than originator; widely used in NHS and European centres for nephrology indications.
• India: Rituximab biosimilars (Maball, Reditux) available at ₹15,000-30,000 per cycle — dramatically lower cost.

Sparsentan (Filspari):

• USA: Approximately $9,500-12,000/month (list price); patient assistance programmes available.
• Not yet approved or widely available outside USA as of 2026.

Mycophenolate mofetil (MMF): £30-60/month (UK NHS generic), $100-200/month (USA generic).

Hospitalisation costs: Acute decompensated nephrotic syndrome with anasarca requiring IV albumin, IV furosemide, and monitoring: UK NHS (no direct cost to patient); private UK £2,000-5,000 per admission; USA $15,000-35,000 per admission; India ₹30,000-80,000 per admission.

Renal biopsy: UK (NHS — no charge); UK private £1,500-2,500; USA $3,000-8,000; India ₹8,000-20,000.

Renal replacement therapy (if progression to ESRD): Haemodialysis: UK NHS £30,000-40,000/year; USA $90,000-120,000/year. Kidney transplantation (one-time): UK £25,000-35,000 (first year); USA $150,000-300,000 (first year). India: transplant ₹5,00,000-12,00,000 (first year).

The nephrology field is rapidly advancing with novel targeted therapies for treatment-resistant nephrotic syndrome:

• Obinutuzumab (Gazyva): Type II anti-CD20 antibody with enhanced B-cell depletion vs rituximab. Phase II RCT (NOBILITY — lupus nephritis) showed superiority; being evaluated for MCD and FSGS. Likely to become next-generation B-cell depleting therapy in difficult-to-treat cases.
• Voclosporin (Lupkynis): Novel calcineurin inhibitor with faster, more predictable pharmacokinetics; FDA-approved 2021 for lupus nephritis; demonstrating efficacy in membranous nephropathy studies. Advantage over tacrolimus: no requirement for dose adjustment in renal impairment based on serum levels.
• Targeted complement therapy: C3 glomerulopathy (C3G) and MPGN — avacopan (C5a receptor inhibitor), pegcetacoplan (C3 inhibitor, Apellis) currently in Phase III trials for complement-mediated nephropathies.
• Atacicept and belimumab (B-cell/BLyS pathway): Under evaluation in IgA nephropathy and lupus nephritis with nephrotic features.
• Gene therapy and podocyte-specific targets: Research-stage interventions targeting TRPC6 channels and podocin mutations in genetic FSGS — not yet in clinical use.
• SGLT2 inhibitors across glomerular diseases: The EMPA-KIDNEY trial (empagliflozin) and DAPA-CKD trial have established SGLT2 inhibitors as standard renoprotective therapy across a wide range of CKD including glomerular diseases, reducing the composite of CKD progression or cardiovascular death by 28-35%.
• Conservative kidney management (CKM): For elderly patients with ESRD who decline dialysis, a structured palliative-focused pathway preserving quality of life — often the most appropriate option when life expectancy from CKD exceeds that from other comorbidities.